News

AmMax to participate in Cowen Conference on March 3rd. Read More>

AmMax Bio, Inc.

Slogan 2020 AmMax white 3 lines.png
shutterstock_1174276207_edited_edited.jp
 
shutterstock_724957504_edited.jpg

ABOUT US​

Launched in March 2020 out of a partnership between LifeMax and Amgen, AmMax Bio, Inc. (“AmMax”) is a privately held, clinical stage biotech company focused on unlocking the therapeutic potential of the CSF1R platform (“colony stimulating factor 1 receptor”) to address diseases with significant unmet medical needs and sizable market potential. We have two clinical stage programs ready to enter Phase 2 studies.

November 30, 2021
AmMax Bio Hosting Key Opinion Leader Webinar on AMB-05X for...

REDWOOD CITY, Calif. Nov 30, 2021 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biotech company developing novel treatments with AMB-05X, its proprietary anti-CSF1R...

October 20, 2021
AmMax Bio Announces Positive Interim Phase 2 Results of AMB-05X...

REDWOOD CITY, Calif. October 20, 2021 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biotech company developing novel treatments with AMB-05X, its proprietary anti-CSF1R...

July 14, 2021
AmMax Bio to Present at the 2nd Annual LifeSci Partners Private...

REDWOOD CITY, Calif. July 14, 2021 —AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing novel treatments with AMB-05X, its proprietary...

NEWS

shutterstock_1682600770_edited.jpg

R&D

AmMax has established a robust pipeline targeting CSF1R. In addition to tenosynovial giant cell tumor wherein an overexpression of CSF1 drives the pathogenesis, AmMax’s pipeline addresses a number of other diseases with critical unmet medical needs, such as idiopathic pulmonary fibrosis and polycystic kidney diseases, by leveraging the action of AMB-05X on inflammation, fibrosis and neovascularization.

Slogan 2020 AmMax white 3 lines.png

News

AmMax Bio Hosting TGCT Key Opinion Leader Webinar...
Read More>